Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TAC-201
- Development stage
- Unknown
- Lead developer
- Triumvira Immunologics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Subcutaneous
01
Overview
TAC-201 is a humanized monoclonal antibody developed by Taiho Pharmaceutical for the treatment of seasonal allergic rhinitis, specifically Japanese cedar pollinosis. It targets Interleukin-33 (IL-33), an alarmin cytokine released from damaged epithelial cells that plays a crucial role in initiating and amplifying Type 2 inflammatory responses. By neutralizing IL-33, TAC-201 aims to inhibit the downstream activation of Th2 cells, ILC2s, and mast cells, thereby reducing allergic symptoms. It is currently being evaluated in Phase 2 clinical trials in Japan using environmental exposure chambers to assess efficacy against pollen challenge.
02
Targets
FCGRT (Neonatal crystallizable fragment receptor)C1Q (Complement C1q)IL33 (IL-33)FcγR (Low affinity immunoglobulin gamma Fc region receptor II-c)
Beyond the preview
Go deeper on TAC-201.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TAC-201.